Lung Cancer Trial, Recruiting (NCT06962670)

Lung Cancer Trial, Recruiting NCT06962670 Sponsor: University of Erlangen-Nürnberg Medical School Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06962670 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who are biologically female and at least 18 years old
People who are willing to sign a written agreement to take part in the study and allow their personal data to be used
People who own a smartphone that can run the BayPass mobile app and are willing to use it for the study

For the cancer group specifically:

People who have been diagnosed (now or in the past) with at least one of the following cancers: breast cancer, lung cancer, colorectal cancer, or a gynecologic cancer (including ovarian, endometrial, cervical, fallopian tube, vaginal, or vulvar cancer)

Who may not be able to join:

People with a known diagnosis of HIV, Hepatitis A, Hepatitis B, Hepatitis C, or who currently have an active COVID-19 (SARS-CoV-2) infection
People who have a serious or potentially life-threatening illness other than the cancers listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthias W. Beckmann, Prof. Dr. med., Head of Department of Obstetrics and Gynecology

Phone: +49 9131 85 33572

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06962670

Sponsor: University of Erlangen-Nürnberg Medical School

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +49 9131 85 33572

More information: https://clinicaltrials.gov/study/NCT06962670

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who are biologically female and at least 18 years old
People who are willing to sign a written agreement to take part in the study and allow their personal data to be used
People who own a smartphone that can run the BayPass mobile app and are willing to use it for the study

For the cancer group specifically:

People who have been diagnosed (now or in the past) with at least one of the following cancers: breast cancer, lung cancer, colorectal cancer, or a gynecologic cancer (including ovarian, endometrial, cervical, fallopian tube, vaginal, or vulvar cancer)

Who may not be able to join:

People with a known diagnosis of HIV, Hepatitis A, Hepatitis B, Hepatitis C, or who currently have an active COVID-19 (SARS-CoV-2) infection
People who have a serious or potentially life-threatening illness other than the cancers listed above

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Erlangen-Nürnberg Medical School

Registry

ClinicalTrials.gov

Start date

14 September 2024

Est. completion

1 September 2025

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Assessment of breast cancer risk by polygenic risk score in combination with app-based self-reported health behavior in the study population

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov